Furthermore, we have shown that AMACR expression is highest in localised prostate cancer and decreases in metastatic disease, and subsequent reductions in AMACR expression in the former is associated with an increased rate of biochemical recurrence (Rubin et al, 2005). The gene discussed is AMACR; the disease is metastatic neoplasm.